Literature DB >> 19780855

Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia.

Marcela Horvitz-Lennon1, Thomas G McGuire, Margarita Alegria, Richard G Frank.   

Abstract

OBJECTIVE: To assess health care disparities among black and Latino adults with schizophrenia receiving services during the period July 1994-June 2006, and to evaluate trends in observed disparities. DATA SOURCES: Administrative claims data from the Florida Medicaid program. Data sources included membership files (demographic information), medical claims (diagnostic, service, and expenditure information), and pharmacy claims (prescriptions used and expenditures). STUDY
DESIGN: We identified adults with at least two schizophrenia claims during a fiscal year. We used generalized estimating equation models to estimate disparities in spending on psychotropic drugs, psychiatric inpatient services, all mental health services, and all health services. PRINCIPAL
FINDINGS: Spending on psychotropic drugs, mental health, and all health was 0.9-70 percent lower for blacks and Latinos than for whites. With the exception of blacks with substance use disorder comorbidity, minorities were less likely than whites to use psychiatric inpatient services. Psychiatric inpatient spending among users did not differ by race/ethnicity. With the exception of psychiatric inpatient utilization/spending, trend analyses showed no change or modest reductions in disparities.
CONCLUSIONS: Black and Latino Medicaid recipients diagnosed with schizophrenia experience health care disparities. Some but not all disparities narrowed modestly over the study period.

Entities:  

Mesh:

Year:  2009        PMID: 19780855      PMCID: PMC2796317          DOI: 10.1111/j.1475-6773.2009.01041.x

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  39 in total

1.  Adequacy of treatment for serious mental illness in the United States.

Authors:  Philip S Wang; Olga Demler; Ronald C Kessler
Journal:  Am J Public Health       Date:  2002-01       Impact factor: 9.308

2.  Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.

Authors:  Nancy H Covell; Carlos T Jackson; Arthur C Evans; Susan M Essock
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

3.  Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

Authors:  Todd P Gilmer; Christian R Dolder; Jonathan P Lacro; David P Folsom; Laurie Lindamer; Piedad Garcia; Dilip V Jeste
Journal:  Am J Psychiatry       Date:  2004-04       Impact factor: 18.112

Review 4.  Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors:  Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

5.  Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States.

Authors:  Gail L Daumit; Rosa M Crum; Eliseo Guallar; Neil R Powe; Annelle B Primm; Donald M Steinwachs; Daniel E Ford
Journal:  Arch Gen Psychiatry       Date:  2003-02

6.  Racial disparity in the pharmacological management of schizophrenia.

Authors:  Julie Kreyenbuhl; Julie M Zito; Robert W Buchanan; Karen L Soeken; Anthony F Lehman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

7.  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

Authors:  Anthony F Lehman; Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon; Richard Goldberg; Lisa D Green-Paden; Wendy N Tenhula; Daniela Boerescu; Cenk Tek; Neil Sandson; Donald M Steinwachs
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

8.  Ethnic disparities in use of public mental health case management services among patients with schizophrenia.

Authors:  Concepcion Barrio; Ann Marie Yamada; Richard L Hough; William Hawthorne; Piedad Garcia; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2003-09       Impact factor: 3.084

9.  Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.

Authors:  Peter J Weiden; Chris Kozma; Amy Grogg; Julie Locklear
Journal:  Psychiatr Serv       Date:  2004-08       Impact factor: 3.084

10.  Disparity in depression treatment among racial and ethnic minority populations in the United States.

Authors:  Margarita Alegría; Pinka Chatterji; Kenneth Wells; Zhun Cao; Chih-nan Chen; David Takeuchi; James Jackson; Xiao-Li Meng
Journal:  Psychiatr Serv       Date:  2008-11       Impact factor: 4.157

View more
  13 in total

1.  Toward the early recognition of psychosis among Spanish-speaking adults on both sides of the U.S.-Mexico border.

Authors:  Rachel Nichole Casas; Edlin Gonzales; Eréndira Aldana-Aragón; María Del Carmen Lara-Muñoz; Alex Kopelowicz; Laura Andrews; Steven Regeser López
Journal:  Psychol Serv       Date:  2014-11

2.  Interviewer-perceived honesty as a mediator of racial disparities in the diagnosis of schizophrenia.

Authors:  Shaun M Eack; Amber L Bahorik; Christina E Newhill; Harold W Neighbors; Larry E Davis
Journal:  Psychiatr Serv       Date:  2012-09-01       Impact factor: 3.084

Review 3.  Measuring racial/ethnic disparities in health care: methods and practical issues.

Authors:  Benjamin Lê Cook; Thomas G McGuire; Alan M Zaslavsky
Journal:  Health Serv Res       Date:  2012-02-21       Impact factor: 3.402

4.  The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries.

Authors:  Marcela Horvitz-Lennon; Julie M Donohue; Judith R Lave; Margarita Alegría; Sharon-Lise T Normand
Journal:  Psychiatr Serv       Date:  2013-03-01       Impact factor: 3.084

5.  Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.

Authors:  Stacie B Dusetzina; Benjamin L Cook; Alisa B Busch; G Caleb Alexander; Haiden A Huskamp
Journal:  Psychiatr Serv       Date:  2013-01       Impact factor: 3.084

6.  Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008.

Authors:  Marcela Horvitz-Lennon; Rita Volya; Julie M Donohue; Judith R Lave; Bradley D Stein; Sharon-Lise T Normand
Journal:  Health Serv Res       Date:  2014-03-13       Impact factor: 3.402

Review 7.  Disparity implications of the Medicare medication therapy management eligibility criteria: a literature review.

Authors:  Kiraat D Munshi; Ya-Chen T Shih; Lawrence M Brown; Samuel Dagogo-Jack; Jim Y Wan; Junling Wang
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2013-04       Impact factor: 2.217

8.  Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy.

Authors:  Robert O Cotes; David R Goldsmith; Sarah L Kopelovich; Cathy A Lally; Benjamin G Druss
Journal:  Community Ment Health J       Date:  2017-11-10

9.  The effect of ethnicity on prescribing practice and treatment outcome in inpatients suffering from schizophrenia in Greece.

Authors:  Athanassios Douzenis; Athanassios Apostolopoulos; Dionisios Seretis; Emmanouil N Rizos; Christos Christodoulou; Lefteris Lykouras
Journal:  BMC Psychiatry       Date:  2011-04-20       Impact factor: 3.630

10.  Use of behavioral health care in Medicaid managed care carve-out versus carve-in arrangements.

Authors:  Christina J Charlesworth; Jane M Zhu; Marcela Horvitz-Lennon; K John McConnell
Journal:  Health Serv Res       Date:  2021-07-26       Impact factor: 3.734

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.